Pediatric oncology researchers have pinpointed a crucial change in a single DNA base that both predisposes children to an aggressive form of the childhood cancer neuroblastoma and makes the disease progress once tumors form.
The change in the LMO1 gene results in a “super-enhancer,” driving abnormally increased biological activity in the gene, resulting in tumor formation and progression. Although this discovery does not lend itself to immediate treatments for this high-risk subtype of neuroblastoma, greater understanding of these precise molecular events may potentially yield novel therapies.
“Cancers in general, and neuroblastoma in particular, have complex origins,” said senior author John M. Maris, MD, a pediatric oncologist at The Children’s Hospital of Philadelphia (CHOP). “It’s not common to discover causal gene variants in cancer, especially in a single base within the DNA sequence such as this.” A change in a single base of DNA is called a single-nucleotide polymorphisms, or SNP.
The study appeared online today in Nature.
A cancer of the peripheral nervous system that usually occurs as a solid tumor in a child’s chest or abdomen, neuroblastoma is the most common cancer in infants. It accounts for a disproportionate share of cancer deaths in children.
By mapping how DNA interacts with regulatory proteins that control transcription, the researchers narrowed down the culprit to the location where a single DNA base, guanine, drives super-enhancer activity, boosting LMO1 gene expression and causing tumors to arise and grow out of control.
The researchers also found that another genetic change has a beneficial effect: If the DNA base at the specified location is a different letter of the genetic alphabet, thymine instead of guanine, it protects against neuroblastoma. Gene studies in human populations suggest that this protective gene variant evolved after human ancestors migrated out of Africa, hundreds of thousands of years ago.
Over the years, researchers at CHOP have discovered a variety of genes contributing to neuroblastoma, and continue to pursue innovative therapies for high-risk, aggressive subtypes of the complex disease.
No existing drugs are known to inhibit the specific proteins that function abnormally in LMO1-driven neuroblastoma. However, adds Maris, other components on this biological pathway may offer attractive treatment targets: “Drugs that inhibit other parts of the gene transcription machinery may offer potential novel treatments for this aggressive subset of neuroblastoma.” Further research at CHOP will pursue that strategy.
Oldridge’s research on the super-enhancer was recognized last month by the International Society of Paediatric Oncology, which presented him with 30th annual Schweisguth Prize, awarded to the best scientific article by a trainee in pediatric oncology.
In addition to his CHOP position, Maris is on the faculty of the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Family Cancer Research Institute.
Funds from the National Institutes of Health (grants CA124709, CA180692, CA151869, MD004418, CA178189, HG000046 and CA109901) supported this research. Other support came from the Press On Foundation, Andrew’s Army Foundation, Alex’s Lemonade Stand Foundation and the Brooke Mulford Foundation, among others.
“Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism,” Nature, published online Nov. 11, 2015. http://doi.org/10.1038/nature15540
Featured in this article
Specialties & Programs
Pediatric oncology researchers have pinpointed a crucial change in a single DNA base that both predisposes children to an aggressive form of the childhood cancer neuroblastoma and makes the disease progress once tumors form.
The change in the LMO1 gene results in a “super-enhancer,” driving abnormally increased biological activity in the gene, resulting in tumor formation and progression. Although this discovery does not lend itself to immediate treatments for this high-risk subtype of neuroblastoma, greater understanding of these precise molecular events may potentially yield novel therapies.
“Cancers in general, and neuroblastoma in particular, have complex origins,” said senior author John M. Maris, MD, a pediatric oncologist at The Children’s Hospital of Philadelphia (CHOP). “It’s not common to discover causal gene variants in cancer, especially in a single base within the DNA sequence such as this.” A change in a single base of DNA is called a single-nucleotide polymorphisms, or SNP.
The study appeared online today in Nature.
A cancer of the peripheral nervous system that usually occurs as a solid tumor in a child’s chest or abdomen, neuroblastoma is the most common cancer in infants. It accounts for a disproportionate share of cancer deaths in children.
By mapping how DNA interacts with regulatory proteins that control transcription, the researchers narrowed down the culprit to the location where a single DNA base, guanine, drives super-enhancer activity, boosting LMO1 gene expression and causing tumors to arise and grow out of control.
The researchers also found that another genetic change has a beneficial effect: If the DNA base at the specified location is a different letter of the genetic alphabet, thymine instead of guanine, it protects against neuroblastoma. Gene studies in human populations suggest that this protective gene variant evolved after human ancestors migrated out of Africa, hundreds of thousands of years ago.
Over the years, researchers at CHOP have discovered a variety of genes contributing to neuroblastoma, and continue to pursue innovative therapies for high-risk, aggressive subtypes of the complex disease.
No existing drugs are known to inhibit the specific proteins that function abnormally in LMO1-driven neuroblastoma. However, adds Maris, other components on this biological pathway may offer attractive treatment targets: “Drugs that inhibit other parts of the gene transcription machinery may offer potential novel treatments for this aggressive subset of neuroblastoma.” Further research at CHOP will pursue that strategy.
Oldridge’s research on the super-enhancer was recognized last month by the International Society of Paediatric Oncology, which presented him with 30th annual Schweisguth Prize, awarded to the best scientific article by a trainee in pediatric oncology.
In addition to his CHOP position, Maris is on the faculty of the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Family Cancer Research Institute.
Funds from the National Institutes of Health (grants CA124709, CA180692, CA151869, MD004418, CA178189, HG000046 and CA109901) supported this research. Other support came from the Press On Foundation, Andrew’s Army Foundation, Alex’s Lemonade Stand Foundation and the Brooke Mulford Foundation, among others.
“Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism,” Nature, published online Nov. 11, 2015. http://doi.org/10.1038/nature15540
Contact us
Cancer Center